Anzeige
Mehr »
Sonntag, 05.10.2025 - Börsentäglich über 12.000 News
Innocan Pharma: Neues Medikament für den Massenmarkt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
03.10.25 | 19:59
161,16 Euro
-0,05 % -0,08
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
160,30160,6204.10.
160,46160,9403.10.

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SaJim Cramer Believes Lawsuits Are No Longer a Major Threat to Johnson & Johnson2
SaNotable analyst calls this week: J&J, PayPal and Corteva among top picks13
FrWells Fargo sees 'room to run' for Johnson & Johnson, highlights pharma upside17
Fr4 stocks to watch on Friday: AAPL, CVX, CBRL, JNJ3
FrHere are Friday's biggest analyst calls: Nvidia, Apple, Broadcom, Tesla, Netflix, Ferrari, Johnson & Johnson, Coinbase & more41
FrJohnson & Johnson is a buy as drug sales continue to improve, Wells Fargo says12
FrJ&J upgraded at Wells Fargo on valuation, pharma potential4
FrThis Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday3
JOHNSON & JOHNSON Aktie jetzt für 0€ handeln
DoNanobiotix gains after early-stage trial data for J&J-partnered cancer drug4
DoJ&J MedTech's orthopedics head joins Dentsply Sirona as CCO5
DoJ&J's Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis2
DoRegulatory tracker: J&J's Tremfya picks up 2 pediatric approvals from FDA4
MiNanobiotix S.A.: NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer102Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective...
► Artikel lesen
MiAKTIEN IM FOKUS 2: US-Deal mit Pfizer hilft gesamter Pharmabranche1.253(Neu: Überschrift, Aktienkurse von Pfizer und weiteren Branchenunternehmen, weitere Analystenkommentare.) NEW YORK/FRANKFURT/PARIS/ZÜRICH/LONDON (dpa-AFX) - Ein Deal zwischen der US-Regierung und...
► Artikel lesen
DiNanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer8
DiWhy JNJ Stock Defines Shareholder Supremacy In Healthcare17
DiPrudential Financial appoints Johnson & Johnson CFO to board14
DiJ&J gets FDA approval for Tremfya in paediatric psoriasis6
DiNanobiotix S.A.: NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC179Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate ("DCR") and...
► Artikel lesen
MoJohnson & Johnson (JNJ): A Dividend Aristocrat With Unmatched Stability10
Weiter >>
671 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
6,2,11